跳至主要内容
临床试验/EUCTR2006-002003-14-DE
EUCTR2006-002003-14-DE进行中(未招募)不适用

Efficacy and tolerability of Triamcinolonacetonide crystalline solution for local treatment of keloids: clinical verum-controlled study in parallel groups with Triam 10 mg Lichtenstein versus Volon A 10.Prospective, double-blind, randomised, clinical multicentre Phase IV study with two treatment groups.Study title in German (see study protocol) Wirksamkeit und Verträglichkeit von Triamcinolonacetonid Kristallsuspension zur lokalen Behandlung von Keloiden: klinischer Verum-kontrollierter Parallelvergleich von Triam 10 mg Lichtenstein versus Volon A 10.Prospektive, doppelblinde, randomisierte, klinische Multizenterstudie der Phase IV mit zwei Behandlungsgruppen.

Winthrop Arzneimittel GmbH0 个研究点开始时间: 2006年9月27日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Females and males aged between 18 and 65 years (Caucasian with pale colour of the skin: sun-reaction reactive skin type I to IV according to Fitzpatrick)
  • 2. Signed informed consent form for study participation and data protection
  • 3. Keloid - neither in face nor on haired head nor in a joint region - which fulfills the following criteria:
  • - height: between 2 to 7 mm
  • - area: between 1,0 to 10 cm2
  • - existing since at least 2 months but not longer than 2 years
  • - MVSS: a score value of at least 10 whereas the height of the scar is at least 2 mm
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Hypertrophic scar or keloid-like changes (acne keloidalis nuchae, pseudofolliculitis barbae) but no keloid
  • 2. Prohibited previous treatments
  • 3. Prohibited local or systemic concomitant treatments
  • 4. Contraindication to an intralesional application of the study medication:
  • - hypersensitivity to triamcinolonacetonide, benzyl alcohol or other ingredients of
  • Triam 10 mg Lichtenstein or Volon A 10
  • - acute viral infection (herpes zoster, herpes simplex, vricelles, herpetic keratitis)
  • - HBs-antigen positive chronic-active hepatitis
  • - approximately 8 weeks prior to until 2 weeks after vaccination with live vaccine
  • - systemic fungal infections or parasitic diseasess (i.e. nematodes), amebiasis
  • - poliomyelitis
  • - lymphadenitis following BCG-vaccination
  • - perioral dermatitis, rosacea, abscess
  • - acute and chronic bacterial (putride) infections
  • - tuberculosis in medical history (be aware of reactivation) - use of study drug
  • together with tuberculostatic medication, only
  • - tuberculotic or syphilitic skin eruptions
  • - severe osteoporosis
  • - hypertension - hard to stabilize
  • - diabetes mellitus - hard to stabilize
  • - psychiatric disease (also in medical history)
  • - convulsive disease
  • - myasthenia gravis
  • - simple or obstructive glaucoma
  • - corneal ulceration or corneal lesion
  • - ulcer disease
  • - severe ulcerative colitis with impending perforation
  • - diverticulitis
  • - enteranastomosis (in the early postoperative period)
  • 5. Values of cortisol clearly above upper limit of normal range
  • 6. Women of childbearing potential without adequate contraception
  • 7. Pregnancy (planned or already existing) or lactation period
  • 8. Severe organic, neurological or psychiatric or dermatologic disease
  • 9. Study participants, who do not agree to passing on their pseudonymous data
  • 10. Participation in another clinical trial (in parallel or within the last 6 months)
  • 11. Patient participated already in this trial
  • 12. Known abuse of alcohol or drugs
  • 13. Study participants who are unable, to understand the nature, scope and possible impact of the study or who are considered to be non-compliant
  • 14. Scheduled removal or vaccation during the course of the study, which which does not allow the patient to meet all visits
  • 15. Poor language skills (German spoken and written)

研究者

发起方
Winthrop Arzneimittel GmbH

相似试验